Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?
-
Narrated by:
-
By:
About this listen
Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001160. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update https://pubmed.ncbi.nlm.nih.gov/37284804/
T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy https://ascopost.com/news/june-2024/t-dxd-improves-progression-free-survival-in-patients-with-breast-cancer-previously-treated-with-endocrine-therapy/
Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34636255/